key: cord-0887582-sjplck9y
authors: Samanta, Jayanta; Gupta, Rohit; Singh, Mini P.; Patnaik, Itish; Kumar, Ashok; Kochhar, Rakesh
title: Coronavirus disease 2019 and the pancreas
date: 2020-10-12
journal: Pancreatology
DOI: 10.1016/j.pan.2020.10.035
sha: 696f9096c7d1147a2e10f62b79fed104b4a829e1
doc_id: 887582
cord_uid: sjplck9y

Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to a world-wide pandemic since its onset in December of 2019. Although, a primary respiratory pathogen, over the ensuing period, its extra-pulmonary effects have come to the forefront. The virus, having multi-organ tropism, has been shown to affect a host of other organs beyond the lung, including the pancreas. The data on pancreatic involvement by COVID-19, however, have been limited. Moreover, whether the effects on the pancreas are due to the direct effects of the virus or is just an epi-phenomenon is debatable. The prevalence of pancreatic injury and degree of injury are the other issues that need to be addressed. Pancreatic cancer has a dismal prognosis and the management of the same in the COVID era needs to be tailored assessing the risk-benefit ratio for the same. Additionally, pancreatic surgery increases not only the morbidity of the patient, but also the risk of the operator and burden on the health care system. Hence, the decision for such major procedures needs to be rationalized for optimum benefit during this pandemic. Similarly, for the endoscopist, pancreatic endoscopy needs to be carefully regulated to reduce risk to both the patient and the physician and yet deliver optimum patient care. This review gives a concise summary of various aspects of pancreatic involvement and pancreatic disease management during this pandemic.

The world has been shaken by the worst pandemic since the Spanish flu of 1918, by a novel coronavirus, SARS-CoV-2. Since its first detection in Wuhan City of China in December 2019, it has ripped through more than 200 countries affecting more than 26 million people and claiming more than 800,000 lives as on 6 th September, 2020 1 . A part of the coronavirus family, coronavirus disease 2019 (COVID-19) is primarily associated with features of pneumonia, respiratory failure and death. However, with passage of time, increasing reports of its multi-system involvement have come forth. COVID-19 has been reported to involve the gastrointestinal (GI) tract, liver, pancreas, cardiovascular system, nervous system, ocular system and so on 2, 3 . Since the report of the first case of COVID-19 having gastrointestinal (GI) complaints 4 , additional reports have explored extra-pulmonary effects of the virus.

Involvement of the pancreas secondary to viral infections is not uncommon. Commonly reported viruses affecting the pancreas include hepatotropic viruses such as hepatitis A, B, E, Epstein Barr virus , coxsackie virus, cytomegalovirus, herpes zoster virus, HIV, and viruses ceasing mumps, measles, and varicella-zoster. The mechanism of a viral infection causing pancreatic injury depends on the type of virus 5 . SARS-CoV-2 has also been found to affect the pancreas to varying degrees.

We here give a concise review of the relevant published articles and have summarized the overall incidence rates for pancreatic involvement in COVID-19. Moreover, strategies to be adopted for the management of patients with pancreatic cancer and those requiring pancreatic surgery have been outlined. The effect of COVID-19 infection on pancreas transplant recipients have also been reviewed. Finally, the recent guidance on the pancreatic endotherapy has been briefed for the practicing gastroenterologists and pancreatologists.

A literature review was carried out through PubMed, Medline and Google Scholar search engines for all relevant English-language articles/abstracts using a search query constructed with the following medical subject heading (MeSH) terms: ("severe acute respiratory syndrome coronavirus 2" OR "COVID-19" OR "coronavirus 2019" OR "SARS-CoV-2") AND ("pancreas" OR "pancreatitis" OR "hyperamylasaemia" OR "pancreatic cancer" OR " pancreatic surgery" OR "pancreatic transplant"). The reference list of the papers, webpages of major gastroenterology and hepatology journals and websites of World Health Organisation (WHO), and Centre for Disease Control (CDC) publications were reviewed and all relevant data extracted. Additional published and unpublished studies from other platforms such as medRxiv and Social Science Research Network (SSRN) were also searched. For the recommendations, all the latest guidelines of the major gastrointestinal and endoscopy societies were reviewed (including online suggestions and pre-proofs) by the authors and were framed into a narrative review.

Corona viruses are a family of viruses that is responsible for a significant fraction of the human common cold. They are enveloped, positive, single stranded RNA viruses that belong to the family Coronaviridae and the order Nidovirales 6 Electron micrograph images reveal its diameter to be 60 -140 nm and appearance of a solar corona (crown like) due to the presence of spikes (diameter of 9-12 nm). A spike glycoprotein ( S Glycoprotein) attaches the virus to the host cell membrane and is a key factor for host range restriction 10 . The virus been identified to have three subtypes: : "A", "B". and "C" 11 . While "A" and "C" subtypes have been reported from USA and Europe, type "B" is found predominantly in East Asia.

Hypothesized to have originated from bats or through pangolins 12 , COVID-19 uses angiotensin converting enzyme 2 (ACE 2) as a receptor akin to SARS-CoV. Pathogenesis for lung injury encompasses attachment of the virus to ACE2 receptor on the lung type 2 alveolar cells. Once the spike protein (S) attaches to the alveolar cells, it leads to a cytokine storm which results in alveolar flooding and denudation of the lining epithelium, hampering oxygen exchange and manifesting clinically as ARDS 13 . This ACE 2 receptor expression is not only present in the lungs, but is also in abundance in the esophageal epithelial cells, absorptive enterocytes of the ileum and colon, cardiovascular and renal tissues, and the pancreas 14 . In fact, messenger RNA levels of ACE2 were found to be higher in pancreas than the lung 15 .

This explains the multi-organ tropism of the virus. ACE 2 expression is noted both in the exocrine pancreatic glands as well as in the islets. The spike protein (S) engages ACE 2 as the entry receptor 16 . Additionally, the cell entry is facilitated by priming of the S protein by transmembrane protease serine 2 (TMPRSS2) or other proteases 17 (Fig 1) . Combined expression of both ACE 2 and TMPRSS2 is needed for the successful virus entry into the cell. In fact, single-cell RNA-sequencing studies have J o u r n a l P r e -p r o o f demonstrated that this co-expression is noted not only in the lung alveolar epithelial type 2 cells, but also in various organs including the pancreatic ß cells 18 . Moreover, the receptor affinity of SARS-CoV-2 to ACE2 is greater compared to SARS-CoV, which can explain the higher efficiency and enhanced transmissibility of SARS-CoV-2 19 . Binding of the virus to ACE 2 receptor mediates pancreatic injury. Dysregulated immune response and cytokine burst have been seen in severe COVID-19 infection with higher levels of interleukin-6 (IL- 6) found to be associated with worse prognosis 20, 21 . Moreover, it has been noted that pancreatic injury was higher in severe disease as compared to milder COVID-19 infection probably as a fallout of the cytokine burst and immune dysregulation 15 .

Obesity is known to be a poor prognostic marker for various critical illness including AP, because of the increased risk for development of organ failure 22, 23 . Obesity entails increased visceral adipose tissue 24 , including intra-pancreatic fat (IPF). On release of pancreatic enzymes during an episode of AP, unsaturated fatty acids (UFAs) of the triglycerides in the adipocytes get released by hydrolysis and perpetuates fat necrosis in AP. The unbuffered portion of the released UFAs leads to cytokine burst, organ failure and end-organ damage. A similar pathogenetic mechanism of cell injury by UFAs has been recently described in COVID-19 infection and has been found to be linked to mortality 25 . Additionally, obesity has been shown to be a risk factor for poor prognosis in COVID-19 infection 26 . Moreover, as mentioned earlier, ACE2, expressed both in adipose tissue and pancreas 15, 27 , is a key receptor for the virus. Thus, this pathway of virus induced lipotoxicity and cytokine storm 28 can explain the pancreatic injury. In fact, the cytokine profile of both AP and COVID-19 infection has been found to be similar, with increased levels of IL-6, IL-8 and IL-10 29 .

In the earlier studies, SARS-CoV had been shown to cause higher fasting plasma glucose levels 30 and the damage of the pancreatic beta cells was incriminated as a cause for development of "acute diabetes" 31 

Although mechanistically, there is a reason to believe that SARS-CoV-2 can cause significant pancreatic injury, the real-world data are quite contrasting. There are only a few studies looking into evidence of pancreatic injury in a cohort of proven COVID-19 patients while the remaining are case reports of evident pancreatitis in COVID-19 patients.

Limited studies have looked into the prevalence of pancreatic injury in COVID-19 patients ( Table 1) Interestingly, pancreatic abnormalities have been more frequently noted in the subgroup of patients having severe COVID disease ( 

Multiple case reports and a few case series have reported clinical AP in the setting of COVID-19 infection ( Table 2) . Most of these cases had severe COVID-19 infection at baseline. However, a few of these cases had no respiratory symptoms to start with [39] [40] [41] . One of the initial reports was that of development of AP in 2 out of 3 COVID-19 positive hospitalised members of a family in Denmark 42 . Alloway et al. 39 reported a case of a 7-yr-old girl with AP without any respiratory symptoms at onset. 

Pancreatitis, acute or chronic, is known to increase morbidity and often have nutritional deficiencies which might lead to compromised immune systems. Gubatan et al. 62 , in an interesting study, found that the prevalence of COVID-19 infection in patients with prior pancreatitis was 7.8% compared to 2.8% of the general population.

In multi-variate analysis, idiopathic pancreatitis was found to be an independent risk factor for COVID-19 infection. Interestingly, none of the patients with past history of pancreatitis developed AP during the COVID-19 infection 62 .

While majority of the autopsy data in COVID-19 have described lung findings, data on pancreatic injury is limited. In an autopsy series of 3 COVID-19 cases by Yao et al. 63 it was noted that only a few islet cells were degenerated while the exocrine pancreas had no abnormality and was negative for SARS-CoV on immunohistochemistry. On the contrary, using a murine monoclonal antibody, Ding et al. 64 demonstrated that SARS-CoV-2 could be detected in multiple organs including J o u r n a l P r e -p r o o f the pancreas in 4 autopsy cases of COVID-19 related death. Lax et al. 65 in another autopsy study, pointed out that 5 out of 11 cases (45.5%) had focal pancreatitis, although none had clinical suspicion of pancreatitis. This high proportion of focal pancreatitis could be part of end-organ damage rather than the actual virus inflicted injury. In another autopsy series, 2 (25%) of the 8 cases had pancreatic abnormalities.

One 22-yr-old man had haemorrhagic, necrotic changes while another 97-yr-old man had microscopic evidence of pancreatitis 66 .

Since viral infections are known to cause pancreatitis 5 and pain abdomen has been a well reported GI symptom among COVID-19 patients 67 , the association of COVID-19 infection with pancreatic injury/inflammation deemed logical. However, a critical analysis of the available data cast doubts on this probable association. As pointed out earlier, most of the cohort studies have used mere elevation of serum amylase/lipase levels as surrogate markers of pancreatic injury. Moreover, only a fraction (2.8% in one study) of these patients had levels >3 times ULN and practically none had robust evidence of clinical AP as per the diagnostic criteria 38 . As raised serum amylase levels are not specific for AP and can have different sources including the healthy and diseased lung 68 . Lipase is more specific for diagnosing AP but is not exclusive.

Lipase levels can be elevated because of various other conditions such as underlying diabetes or renal dysfunction 69 , critical illness 70 or drugs such as corticosteroids 71 .

All of these factors are commonly encountered in COVID-19 positive patients.

Since GI involvement in COVID-19 is well documented, increased intestinal permeability secondary to SARS-CoV-2 infection can lead to increased pancreatic J o u r n a l P r e -p r o o f enzyme levels 72 . Gastroenteritis is also known to cause hyperamylasaemia 73 .

Interestingly, COVID-19 patients with pancreatic abnormalities, as mentioned above, had higher prevalence of GI symptoms. Thus, GI involvement, by itself, can explain the isolated rise in the amylase/lipase without associated pancreatitis in this group of patients.

Elevated pancreatic enzymes or AP can also be secondary to cytokine storm and multi-organ dysfunction leading to pancreatic injury rather than the direct cytopathic effects of the virus. Mechanical ventilation or shock, too, can lead to hypoxic pancreatic damage 74 . This corroborates with the evidence that pancreatic injury was higher among patients with more severe disease.

Multiple drugs such as corticosteroids and NSAIDs used during management of COVID-19 can precipitate pancreatitis 75 

The interaction of COVID-19 with pancreatic endocrine system complicates the scenario for patients with diabetes mellitus (DM) infected with the virus. DM with associated hyperglycemia has been found to have poor prognosis with increased morbidity and mortality 79, 80 . This can be explained to be secondary to depressed innate immune response and exaggerated cytokine response in DM 81 

Presence of comorbidities not only pre-disposes to increased likelihood of being infected with COVID-19 but also leads to a more severe disease course 79 . Cancer has been found to be a risk factor for increased likelihood of infection and also severe disease 82 , more so with lung and colorectal cancer 83 . In one study, pan-cancer analysis showed pancreatic adenocarcinoma to have increased ACE2 expression 84 , and deep deletions for TMPRSS2 85 .

This may hint towards increased baseline risk in this group of patients. Moreover, chemotherapeutic drugs, when used for management of pancreatic cancer, cause immunosuppression leading to added risk. A very high rate (40%) of adverse events and complications has been reported with chemotherapeutic regimens in COVID-19 patients 86 .

Pancreatic cancer, as such, has a very dismal prognosis. The added risk of this pandemic warrants more careful assessment of the risk-benefit ratio. While major pancreatic oncosurgeries have a high morbidity and complications rate, chemotherapy treatment can compound the risk. Thus, the decision for medical and surgical therapy needs to be tailor made after a multi-disciplinary team consultation 87, 88 . A tiered approach has been advocated to prioritise various interventions for optimum benefit: i) tier 1 (high priority) includes life threatening conditions or where there is significant improvement in the survival; ii) tier 2 (medium priority) encompasses condition where a 6-8 weeks delay would not hamper the overall outcome; iii) tier 3 (low priority) entails stable patient conditions wherein services can be delayed for the pandemic to be over or situation where there will be no survival gain.

European Society for Medical Oncology (ESMO) 89 Endoscopists need to assess the following: i) need for the procedure -risk benefit ratio; b) if the procedure is time sensitive, then whether it is urgent (< 2weeks) or semi-urgent (2-8 weeks); iii) if the procedure can be deferred beyond 8 weeks 102 . Important parameters that need to be reviewed include threat to patient's life, risk of disease progression/worsening or risk of metastasis. Thus, ERCP for obstructive jaundice or cholangitis, EUS guided drainage for infected/symptomatic pancreatic fluid collection or for fine needle aspiration/biopsy for pancreatic lesion/cyst without metastatic lesions may be carried out on a priority basis 103 .

Endotherapy for chronic pancreatitis, celiac plexus block, evaluation for idiopathic/recurrent pancreatitis etc. can be deferred. The precautions to be taken during the procedure have been outlined in various society guidelines.

Although mechanistically SARS-CoV-2 is expected to cause pancreatic injury, robust realworld data on its actual impact is lacking. The elevation of serum levels of pancreatic enzymes, amylase and lipase, has been considered as a marker of pancreatic injury and attributed to the effect of COVID-19 infection. However, actual evidence of clinical pancreatitis secondary to SARS-CoV-2 is dubious. Whether this reported pancreatic enzyme elevation in COVID-19 positive patients, more for severe cases, has a cause-effect relationship or just an epiphenomenon needs to be established. Larger data and international registries focused on this aspect can possibly give an answer. Pancreatic cancer management and pancreatic surgeries in this COVID era have to be tailor made to individual cases after multi-disciplinary assessment of the available options and the risk-benefit ratio. Interventions J o u r n a l P r e -p r o o f including pancreatic endotherapy not only burdens the over-stretched health system in this COVID era, but also increases risk for health care workers. Thus, triaging of cases and catering to only the essential ones are recommended. Adequate precaution, avoiding elective cases, and "lying low" in terms of interventions are the key strategies that will enable the gastroenterologists and pancreatologists to tide over this COVID-19 crisis 

Patients with newly diagnosed resectable cancer to be consulted on high priority, preferably through telemedicine, along with multi-disciplinary assessment for plan for surgery. Unstable patients or those requiring interventions such as jaundice, cholangitis, post-surgical complications etc to be given priority Patients with established diagnosis with minor problems should be directed towards telemedicine. Post-operative patients with no complications or with no issues should be discouraged from OPD visits.

Symptomatic patients, such as jaundice or intestinal occlusion should be given priority For diagnosis of pancreatic cancer, CT followed by EUS, if resectable, need to be considered Routine follow up for recurrence or restaging after surgery needs to be kept on low priority

Resectable malignancy including cystic lesions with suspicion of malignancy to be kept high priority Endoscopic stenting for biliary obstruction, cholangitis, or for those planned for neoadjuvant/palliative treatment should be carried out on high priority Post-surgical complications to be managed promptly For non-resectable diseases/metastatic diseases with life expectancy >3 months, biliary or duodenal obstruction can be managed with hepatojejunostomy/hepatogastrojejunostomy/ endoscopic stenting can be done with lower priority • Medical oncology priorities For localised or locally advanced disease o Initiation or completion of neoadjuvant/adjuvant treatment with high priority o Adjuvant treatment to be initiated with ECOG PS 0, <70 yrs. old, based on pathologic state and individual risk assessment o Modified FOLFIRINOX regimen to be considered, and delaying treatment up to 12 weeks after surgery o Follow up imaging or restaging in asymptomatic cases to be deferred For advanced/metastatic disease o First line chemotherapy likely to improve survival in patients who can tolerate combined regimen o Monotherapy regimen for asymptomatic/oligosymptomatic cases to be assessed based on the risk-benefit ratio o Follow-up imaging/restaging studies to be deferred o Anti-resorptive therapy such as zolendronate to be deferred Prophylactic use of G-CSF for minimising neutropenia-associated risks is debatable Adequate venous thromboprophylaxis to be provided J o u r n a l P r e -p r o o f 

COVID-19) Dashboard 2020

Novel Coronavirus Infection: Gastrointestinal Manifestations

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

First case of 2019 novel coronavirus in the United States

Review of infectious etiology of acute pancreatitis

Genetic Recombination, and Pathogenesis of Coronaviruses

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Host Factors in Coronavirus Replication

Phylogenetic network analysis of SARS-CoV-2 genomes

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme

ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection

Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Extrapulmonary manifestations of COVID-19

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Obesity increases the severity of acute pancreatitis: performance of APACHE-O score and correlation with the inflammatory response

Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity

Obesity and pancreatitis

Mortality From Coronavirus Disease 2019 Increases With Unsaturated Fat and May Be Reduced by Early Calcium and Albumin Supplementation

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

Pancreatic triglyceride lipase mediates lipotoxic systemic inflammation

Lipotoxicity and Cytokine Storm in Severe Acute Pancreatitis and COVID-19

Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

COVID-19 may affect the endocrine pancreas by activating Na(+)/H(+) exchanger 2 and increasing lactate levels

Viruses and diabetes

Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-so-rare occurrence

Lipase Elevation in Patients With COVID-19

Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia

Marked Elevation of Lipase in COVID-19 Disease: A Cohort Study

Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus

Suspected case of COVID-19-associated pancreatitis in a child

COVID-19 presenting as acute pancreatitis: Lessons from a patient in Iran

First case of acute pancreatitis related to SARS-CoV-2 infection

Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members

COVID-19-Associated Multisystem Inflammatory Syndrome in Children Presenting as Acute Pancreatitis

COVID-19 infection presenting as pancreatitis in a pregnant woman: A case report

Recurrent Acute Pancreatitis in a Patient with COVID-19 Infection

SARS-CoV2 RNA detection in a pancreatic pseudocyst sample

Emerging phenotype of SARS-CoV2 associated pancreatitis

Acute pancreatitis and nosocomial COVID-19: Cause specific host responses may determine lung injury

Prevalence, risk factors, and outcomes of hospitalized patients with COVID-19 presenting as acute pancreatitis

Clinical Outcomes of Acute Pancreatitis in Patients with COVID-19

Acalculous Acute Pancreatitis in a COVID-19 Patient

COVID-19 presenting as acute pancreatitis

Acute pancreatitis in a COVID-19 patient

Pancreatic involvement in SARS-CoV-2: case report and living review

Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab

Report: Novel Coronavirus-A Potential Cause of Acute Pancreatitis?

Acute pancreatitis in a patient with COVID-19 infection

COVID-19-associated acute pancreatitis: a rare cause of acute abdomen

Acute pancreatitis in a 61-year-old man with COVID-19

COVID-19 Induced Acute Pancreatitis: A Case Report and Literature Review

Hyperglycemia, hypertriglyceridemia, and acute pancreatitis in COVID-19 infection: clinical implications

risk factors and clinical outcomes of COVID-19 in patients with a history of pancreatitis in Northern California

A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua bing li xue za zhi=

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a

Clinicopathologic Case Series

Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study

Don't Overlook Digestive Symptoms in Patients With

Novel Coronavirus Disease (COVID-19)

Amylase changes in disorders of the lung

LEADER 3-lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial

Clinical significance of increased lipase levels on admission to the ICU

Prevalence and determinants of increased serum lipase levels in a general population

Where does serum amylase come from and where does it go?

Pancreatic hyperamylasemia during acute gastroenteritis: incidence and clinical relevance

PANCREATITIS OR NOT?--Elevated lipase and amylase in ICU patients

Drug induced pancreatitis

Baricitinib as treatment for COVID-19: friend or foe of the pancreas?

High-Dose Prednisone for Treatment of Autoimmune Pancreatitis in a Patient with Coronavirus Disease 2019 (COVID-19) due to Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Position statement within the framework of the SARS-CoV-2 (COVID-19) pandemic

Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

The single nucleotide polymorphism rs11643718 in SLC12A3 is associated with the development of diabetic kidney disease in Chinese people with type 2 diabetes

COVID-19 and diabetes mellitus: An unholy interaction of two pandemics

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Which type of cancer patients are more susceptible to the SARS-COX-2: Evidence from a meta-analysis and bioinformatics analysis

Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis

Pancancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARSCoV2 infection leading to COVID-19

Management of Pancreatic Cancer During COVID-19 Pandemic: To Treat or Not to Treat?

Cancer guidelines during the COVID-19 pandemic

Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic

ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer

Systemic treatment of patients with gastrointestinal cancers during the COVID-19 outbreak: COVID-19-adapted recommendations of the National Cancer Institute of Milan

COVID-19: Guidance for Triage of Non-Emergent Surgical Procedures 2020

Global Survey on Pancreatic Surgery During the COVID-19 Pandemic

Delivery of hepato-pancreato-biliary surgery during the COVID-19 pandemic: an European-African Hepato-Pancreato-Biliary Association (E-AHPBA) crosssectional survey

Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic

COVID 19 infection in pancreas transplant recipients

Fatal Outcome in a Kidney-Pancreas Transplant Recipient With COVID-19. Cureus

First experience of SARS CoV 2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study

Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements)

Considerations in performing endoscopy during the COVID-19 pandemic

Air suctioning during colon biopsy forceps removal reduces bacterial air contamination in the endoscopy suite

Risk of bacterial exposure to the endoscopist's face during endoscopy

GI society message: COVID-19 clinical insights for our community of gastroenterologists and gastroenterology care providers

Pancreaticobiliary Endoscopy in the COVID-19 Pandemic Era

We acknowledge BioRender for design support for